MAK31 Antibody

What is MAK31 and what is its primary biological function?

MAK31 is a component of the NatC N-terminal acetyltransferase complex that catalyzes the acetylation of N-terminal methionine residues in nascent polypeptides. It plays a crucial role in the L-A virus function in yeast and is involved in various cellular processes including protein stability, localization, and function. The NatC complex in yeast is composed of three subunits: Mak3, Mak10, and Mak31. Together, these components form an enzymatic complex essential for post-translational protein modification.

How does MAK31 in yeast compare to its human homolog?

When studying the human homolog, researchers should note that NAA30 knockdown induces p53-dependent apoptosis and growth arrest, and the protein interacts with lysosomal trafficking proteins such as hArl8b.

What phenotypes are associated with MAK31 deficiency?

MAK31-deficient yeast strains exhibit several characteristic phenotypes that highlight the protein's biological importance:

Additionally, MAK31 deficiency creates synthetic lethality with genes involved in DNA replication, suggesting a role in genome integrity maintenance.

What approaches should be used to select antibodies for MAK31/NAA30 detection?

While MAK31-specific antibodies are not extensively documented in commercial catalogs, researchers typically employ indirect detection methods:

For yeast MAK31 studies:

• Epitope tagging: Using anti-HA-tag antibodies (e.g., ab9110) to detect epitope-tagged MAK31 variants constructed through genetic engineering.

• Custom antibody development: Designing peptide-based immunogens from conserved MAK31 regions for antibody production.

For human NAA30 studies:

• Commercial anti-NAA30 antibodies (e.g., Sigma HPA057824) for Western blotting and immunoprecipitation applications.

• Validation against cell lines with CRISPR knockout or siRNA knockdown of NAA30.

These approaches should be selected based on the specific experimental requirements and available resources.

How can researchers validate the specificity of antibodies targeting MAK31/NAA30?

Validating antibody specificity is crucial for reliable research outcomes. For MAK31/NAA30 antibodies, consider the following validation protocol:

• Genetic controls: Test antibody reactivity in wild-type versus MAK31/NAA30 knockout or knockdown samples to confirm signal specificity.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to demonstrate signal blocking in specific binding.

• Orthogonal detection methods: Correlate antibody-based detection with orthogonal techniques such as mass spectrometry or RNA expression analysis.

• Biophysics-informed modeling: As demonstrated in recent research, computational modeling can help predict antibody specificity based on binding modes associated with specific ligands .

• Cross-reactivity testing: Examine antibody reactivity against closely related proteins (other NatC components) to ensure specificity.

Researchers should document these validation steps meticulously to support data reproducibility and reliability.

What flow cytometry approaches are optimal for detecting MAK31/NAA30 in cellular samples?

When designing flow cytometry experiments to detect MAK31/NAA30:

• Fixation and permeabilization optimization: Since MAK31/NAA30 is an intracellular protein, thorough optimization of fixation and permeabilization conditions is essential. Test multiple protocols (e.g., methanol, paraformaldehyde/saponin) to determine optimal conditions for epitope preservation.

• Fluorochrome selection: Choose bright fluorochromes like R-phycoerythrin or allophycocyanin for detection of low-abundance proteins such as MAK31/NAA30 .

• Magnetic enrichment: For rare cell populations expressing MAK31/NAA30, consider using magnetic nanoparticles conjugated to antibodies targeting the fluorochrome to enrich cells prior to flow cytometry analysis .

• Controls and standardization: Include appropriate negative controls (isotype, fluorescence-minus-one) and positive controls (overexpression systems) to establish detection thresholds.

• Panel design: Carefully design flow cytometry panels to avoid emission spillover into the channel for MAK31/NAA30 detection .

When publishing flow cytometry data, ensure comprehensive reporting of all experimental parameters according to established guidelines .

What immunoprecipitation methods work best for MAK31/NAA30 protein complex studies?

For efficient immunoprecipitation of MAK31/NAA30 and associated proteins:

• Lysis buffer optimization: Test multiple lysis conditions (varying detergents, salt concentrations) to maintain complex integrity while achieving efficient extraction.

• Cross-linking considerations: For transient or weak interactions, implement reversible cross-linking (e.g., DSP, formaldehyde) prior to cell lysis.

• Antibody coupling strategies: Covalently couple antibodies to beads (protein A/G, magnetic) to prevent antibody contamination in downstream applications.

• Sequential immunoprecipitation: For specific subcomplex analysis, implement sequential immunoprecipitation targeting different complex components.

• Validation by mass spectrometry: Confirm immunoprecipitation results with mass spectrometry to identify specific and non-specific interactions.

These approaches can reveal novel protein interactions and functional relationships within the NatC complex.

How can researchers develop assays to study MAK31/NAA30 enzymatic activity?

To effectively measure the N-terminal acetyltransferase activity of MAK31/NAA30:

• Substrate identification: Select appropriate peptide substrates based on known NatC recognition motifs (typically peptides with N-terminal Met followed by hydrophobic residues).

• Activity assays:

  • Radiometric assays: Using [14C]-acetyl-CoA or [3H]-acetyl-CoA to track acetyl group transfer

  • HPLC-based assays: Monitoring substrate and product peaks

  • Colorimetric assays: Utilizing specific dyes that change properties upon acetylation

  • Mass spectrometry: Directly measuring mass shifts associated with acetylation

• Inhibitor screening: Develop high-throughput assays to identify specific inhibitors of MAK31/NAA30-containing complexes.

• Kinetic analysis: Determine key enzymatic parameters (Km, Vmax, kcat) for wild-type and mutant proteins to understand structure-function relationships.

These approaches can provide insights into the molecular mechanisms of N-terminal acetylation and its biological consequences.

What approaches should be used to investigate MAK31/NAA30 in disease contexts?

The human homolog NAA30 has emerging implications in cancer biology and other diseases. To investigate these connections:

• Expression profiling: Analyze NAA30 expression across normal and diseased tissues using antibody-based techniques (immunohistochemistry, Western blotting) and correlate with patient outcomes.

• Functional genomics: Apply CRISPR/Cas9 or RNAi techniques to modulate NAA30 expression in disease models and assess phenotypic consequences.

• Substrate identification: Employ proteomics approaches to identify differentially acetylated proteins in disease states versus normal conditions.

• Animal models: Develop conditional knockout models to study tissue-specific roles of NAA30 in disease progression.

• Patient-derived samples: Analyze NAA30 function in patient-derived cells or organoids to establish clinical relevance.

These investigations could potentially identify NAA30 as a therapeutic target or biomarker for specific disease conditions.

What are common challenges in MAK31/NAA30 research and how can they be addressed?

Researchers working with MAK31/NAA30 often encounter several technical challenges:

• Low abundance detection:

  • Challenge: MAK31/NAA30 may be expressed at low levels in certain cell types.

  • Solution: Implement signal amplification methods (e.g., tyramide signal amplification), use highly sensitive detection systems, or employ epitope-tagged constructs.

• Cross-reactivity:

  • Challenge: Antibodies may cross-react with related N-terminal acetyltransferases.

  • Solution: Thoroughly validate antibody specificity using knockout controls and peptide competition assays.

• Complex integrity:

  • Challenge: Maintaining NatC complex integrity during experimental procedures.

  • Solution: Optimize extraction conditions, consider native purification methods, and implement cross-linking approaches when appropriate.

• Functional redundancy:

  • Challenge: Functional redundancy between different N-terminal acetyltransferases.

  • Solution: Conduct combinatorial knockdown/knockout experiments and implement substrate-specific assays.

• Activity preservation:

  • Challenge: Maintaining enzymatic activity during purification.

  • Solution: Use rapid purification protocols, include stabilizing agents, and assay activity at multiple purification stages.

Addressing these challenges requires careful experimental design and methodology optimization.

What standards should be followed when reporting MAK31/NAA30 antibody-based research?

To ensure reproducibility and reliability in MAK31/NAA30 antibody-based research, adhere to these reporting standards:

• Antibody documentation:

  • Complete antibody information (source, catalog number, lot, concentration)

  • Validation methods and results

  • RRID (Research Resource Identifier) when available

• Experimental conditions:

  • Detailed protocols for sample preparation, fixation, permeabilization

  • Buffer compositions and incubation parameters

  • Controls used (positive, negative, isotype)

• Data acquisition parameters:

  • For flow cytometry: cytometer configuration, PMT voltages, compensation matrix

  • For imaging: microscope specifications, exposure settings, processing algorithms

• Analysis methodology:

  • Gating strategies or analysis parameters

  • Software used with version numbers

  • Statistical methods applied

• Data presentation:

  • Representative raw data

  • Clear labeling of axes and units

  • Transparent reporting of replicate numbers and variability

These standards align with broader initiatives for antibody validation and flow cytometry data reporting .

How can single-cell technologies enhance MAK31/NAA30 research?

Single-cell technologies offer unprecedented insights into cellular heterogeneity relevant to MAK31/NAA30 research:

• Single-cell RNA sequencing:

  • Reveals cell-type-specific expression patterns of MAK31/NAA30

  • Identifies co-expression networks providing functional context

  • Enables trajectory analysis to study dynamic regulation during cellular processes

• Mass cytometry (CyTOF):

  • Allows simultaneous detection of MAK31/NAA30 along with dozens of other proteins

  • Reduces spectral overlap issues encountered in flow cytometry

  • Facilitates comprehensive phenotyping of MAK31/NAA30-expressing cells

• Spatial transcriptomics:

  • Preserves spatial context of MAK31/NAA30 expression within tissues

  • Enables correlation with microenvironmental factors

• Multimodal approaches:

  • Combining barcoded tetramers with oligonucleotide-conjugated antibodies and RNA-seq

  • Simultaneously measuring protein and gene expression of MAK31/NAA30-expressing cells

  • Generating unbiased multi-omic information about individual cells

These technologies are poised to revolutionize our understanding of MAK31/NAA30 biology in normal and disease states.

What computational approaches can advance MAK31/NAA30 antibody development?

Advanced computational methods are transforming antibody development for challenging targets like MAK31/NAA30:

• Biophysics-informed modeling:

  • Training models on experimentally selected antibodies to predict binding modes

  • Generating antibody variants with customized specificity profiles

  • Predicting cross-reactivity with related proteins

• Epitope prediction:

  • Identifying immunogenic regions of MAK31/NAA30 for targeted antibody development

  • Selecting peptides with optimal surface exposure and uniqueness

  • Predicting potential cross-reactivity with other proteins

• Antibody structure prediction:

  • Modeling antibody-antigen interactions to optimize binding properties

  • Designing antibodies with enhanced specificity for MAK31 versus related proteins

  • Virtual screening of antibody libraries to identify promising candidates

• Machine learning approaches:

  • Training models on experimental data to identify patterns associated with successful antibodies

  • Optimizing antibody properties based on sequence-function relationships

  • Predicting performance in different applications (Western blot, IHC, flow cytometry)

These computational approaches complement experimental methods and accelerate the development of high-quality research reagents.